ChromaDex - About the company
ChromaDex is a public company based in Longmont (United States), founded in 1999 by Frank Jaksch. It operates as a Developer of nutritional ingredients for health and wellness. ChromaDex has raised $3.39M in funding. The company has 11 active competitors, including 2 funded and 1 that has exited. Its top competitors include companies like Decode Age, Mimio Health and The Oak Age.
Company Details
Developer of nutritional ingredients for health and wellness. The company is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels that decline with age. It delivers Niagen as the sole active ingredient in its consumer product known as Tru Niagen.
- Website
- chromadex.com
- Email ID
- *****@chromadex.com
- Phone Number
- +1 **********
- Registered Address
- Irvine, California
Key Metrics
Founded Year
1999
Location
Longmont, United States
Stage
Public
Total Funding
$3.39M in 23 rounds
Latest Funding Round
Investors
Ranked
2nd among 11 active competitors
Annual Revenue
$50M - $100M as on Dec 31, 2024
Employee Count
50 - 199 as on Mar 01, 2026
Similar Companies
Exit Details
Public
Legal entities associated with ChromaDex
ChromaDex is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Chromadex, Inc. CIN: 20208000993 , United States, Active | Nov 19, 2020 | - | - | - |
CHROMADEX CORP. CIN: 1386570 , United States, Active | Jun 18, 2008 | $50M - $100M (As on Dec 31, 2024) | 106 (As on Dec 31, 2023) | - |
CHROMADEX, INC. CIN: 330880006 , United States, Active | Dec 31, 1999 | - | 106 (As on Dec 31, 2024) | - |
ChromaDex's IPO details
ChromaDex got listed on Jul 21, 2008.
Click here to take a look at ChromaDex's IPO in detail
Sign up to download ChromaDex's company profile
ChromaDex's funding and investors
ChromaDex has raised a total funding of $3.39M over 23 rounds. Its first funding round was on Feb 2007. ChromaDex has 5 institutional investors.
Here is the list of recent funding rounds of ChromaDex:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 22, 2021 | 9479889 | Post IPO | 7214817 | 2814998 | 7281108 | 8249341 |
May 20, 2020 | 4391318 | Post IPO | 9761547 | 1498180 | 5287951 | 5111112 |
Aug 28, 2019 | 4884927 | Post IPO | 1400447 | 5424951 | 2620370 | 1596414 |
View details of ChromaDex's funding rounds and investors
ChromaDex's founders and board of directors
Founder? Claim ProfileThe founders of ChromaDex is Frank Jaksch.
Here are the details of ChromaDex's key team members:
- Frank Jaksch: Co-Founder of ChromaDex. Contact Info: 1 email address
View details of ChromaDex's Founder profiles and Board Members
ChromaDex's employee count trend
ChromaDex has 50 - 199 employees as of Mar 26. Here is ChromaDex's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ChromaDex's Competitors and alternates
Top competitors of ChromaDex include Decode Age, Mimio Health and The Oak Age. Here is the list of Top 10 competitors of ChromaDex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Decode Age 2021, Bengaluru (India), Seed | Online retailer of longevity supplements and provider of microbiome tests | $2.29M | 58/100 | |
2nd | ChromaDex 1999, Longmont (United States), Public | Developer of nutritional ingredients for health and wellness | $3.39M | 54/100 | |
3rd | Mimio Health 2021, San Francisco (United States), Seed | Developer of a fasting-mimetic supplement to optimize metabolism and support longevity. This supplement is designed to mimic the cellular benefits of prolonged fasting without requiring dietary restriction. It utilizes a biomimetic formula containing clinically-validated fasting metabolites to activate cellular processes such as autophagy, mitophagy, and cellular stress response. The product aims to improve metabolism, reduce appetite, enhance mood and cognition, and support healthy aging. The formulation is vegan, gluten-free, GMO-free, and GMP certified. | $2.5M | 32/100 | |
4th | The Oak Age 2023, Chennai (India), Unfunded | Provider of nutritional supplements focused on longevity and healthy aging | - | - | 31/100 |
5th | Online retailer of supplements and skincare products focused on longevity | - | - | 25/100 | |
6th | Spritz Health 2026, Unfunded | Manufacturer of science backed longevity wellness sprays for health performance | - | - | 24/100 |
7th | ![]() Euda Helix Singapore (Singapore), Unfunded | Provider of deer placenta supplement formulated for youthful vitality and protection | - | - | 24/100 |
8th | Bryan Johnson 2002, Los Angeles (United States), Unfunded | Developer of health protocols and nutritional programs for human longevity | - | - | 23/100 |
9th | Mitocholine London (United Kingdom), Unfunded | Developer of nutritional supplements designed to support cellular mitochondrial function | - | - | 16/100 |
10th | ![]() Lnutra.com 2010, Unfunded | Provider of plant-based nutrition solutions | - | - | 16/100 |
Looking for more details on ChromaDex's competitors? Click here to see the top ones
ChromaDex's Investments and acquisitions
ChromaDex has made no investments or acquisitions yet.
Reports related to ChromaDex
Here is the latest report on ChromaDex's sector:
News related to ChromaDex
•
•
ChromaDex GAAP EPS of $0.09 beats by $0.07, revenue of $29.1M beats by $2.59MSeeking Alpha•Mar 04, 2025•ChromaDex
•
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryBusiness Wire•Dec 03, 2024•ChromaDex
•
BSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC)MarketBeat•Nov 04, 2024•BSW Wealth Partners, ChromaDex
•
ChromaDex Corporation Reports Third Quarter 2024 Financial ResultsBusiness Wire•Nov 01, 2024•ChromaDex
•
ChromaDex GAAP EPS of $0.02 beats by $0.01, revenue of $25.58M beats by $1.71MSeeking Alpha•Oct 31, 2024•ChromaDex
•
•
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness ClinicsBusiness Wire•Sep 10, 2024•ChromaDex
•
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+Business Wire•Aug 19, 2024•ChromaDex
•
ChromaDex Corporation Reports Second Quarter 2024 Financial ResultsBusiness Wire•Aug 08, 2024•ChromaDex
Are you a Founder ?
FAQs about ChromaDex
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
